@jkb92 Joa, one bad piece of news/study that is missed and it goes straight down, but I also think the way the market reacts to it is partly exaggerated.
@NotBubble I understand FCF yields pretty well and like to pick best of the bests and there are also companies in the sector that meet tough requirements like this.🤷🏼♂️
@jkb92 pipeline is actually quite full but I haven't bought yet because they are stuck in the range, if the breakout comes whether up or down it will shoot volatile in that direction
@Investingyoung$BNTX, $KRYS and $4519 are all extremely cash-rich for biotech. In the case of $KRYS, there is also the strong pipeline, and in the case of $4519, the large stake held by $ROG is the main attraction, as this ensures that Chugai only has to pay for R&D and simply has access to Roche's entire sales structure for everything it has developed.
